Risperdal Safety Protocol Evaluation Consta Treatment; A Post Authorisation Safety Survey With RISPERDAL CONSTA TM

Trial Profile

Risperdal Safety Protocol Evaluation Consta Treatment; A Post Authorisation Safety Survey With RISPERDAL CONSTA TM

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2010

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Acronyms RiSPECT
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 19 Oct 2007 Status changed from in progress to completed.
    • 18 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top